Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Patent
1997-04-03
1999-11-09
Harrison, Robert H.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
424 952, 424491, 424493, A61K 950
Patent
active
059809507
ABSTRACT:
The foregoing invention relates to a new microbubble preparation and thrombolytic therapy which relies on microbubbles and ultrasound for its lytic activity. The pharmaceutical composition of the invention comprises a liquid solution of microbubbles with an internal atmosphere enhanced with the perfluorocarbon gas which cavitate in the presence of an ultrasound field following intravenous injection or infusion of said composition into said host. For thrombolysis the area of a thrombus is exposed to an ultrasound field in the presence of the microbubbles and significant lysis is experienced. The method and pharmaceutical composition of the invention exhibit thrombolytic properties similar to those of other thrombolytic agents such as urokinase and are less toxic and are clot specific in that they do not introduce a systemic lytic state to a said animal.
REFERENCES:
patent: 4572203 (1986-02-01), Feinstein
patent: 4718433 (1988-01-01), Feinstein
patent: 4957656 (1990-09-01), Cerny et al.
patent: 5040537 (1991-08-01), Katakura
patent: 5310540 (1994-05-01), Giddey et al.
patent: 5315998 (1994-05-01), Tachibana et al.
patent: 5380519 (1995-01-01), Schneider et al.
patent: 5385725 (1995-01-01), Lin et al.
patent: 5393524 (1995-02-01), Quay
patent: 5401493 (1995-03-01), Lohrmann et al.
patent: 5409688 (1995-04-01), Quay
patent: 5413774 (1995-05-01), Schneider et al.
patent: 5445813 (1995-08-01), Schneider et al.
patent: 5512268 (1996-04-01), Grinstaff et al.
patent: 5542935 (1996-08-01), Unger et al.
patent: 5552133 (1996-09-01), Lambert et al.
patent: 5558853 (1996-09-01), Quay
patent: 5560364 (1996-10-01), Porter
patent: 5567415 (1996-10-01), Porter
patent: 5639443 (1997-06-01), Schutt et al.
patent: 5648098 (1997-07-01), Porter
patent: 5695460 (1997-12-01), Siegel et al.
patent: 5846517 (1998-12-01), Unger
patent: 5849727 (1998-12-01), Porter et al.
Srinivasan, S., (1995), "Characterization of Binding Sites, Extend of Binding, and Drug Interactions of Oligonucleotides with Albumin", Antisense Research and Development, 5:131-139; Mary Ann Liebert, Inc.
Porter, T., (1995), "Visually Discernible Myocardial Echocardiographic Contrast After Intravenous Injection of Sonicated Dextrose Albumin Microbubbles Containing High Molecular Weight, Less Soluble Gases", JACC, 25(2):509-515.
Porter, T., (1994), "Multifold Sonicated Dilutions of Albumin With fifty Percent Dextrose Improve Left Ventricular Contrast Videointensity After Intravenous Injection in Human Beings", J. Am. Soc. of Echocardiography, 7(5):466-471.
Xei, F., 1994, "Acute Myocardial Ischemia and Reperfusion can be Visually Identified Non-invasively with Intravenous Perfluoropropane-Enhanced Sonicated Dextrose Albumin Ultrasound Contrast", Abstracts From the 67th Scientific Sessions, Dallas Convention Center, Dallas, Texas, Nov. 14-17, 1994; 90(4) part 2, p. 2989.
Porter, T., (1995), "Noninvasive Identification of Acute Myocardial Ischemia and Reperfusion with Contrast Ultrasound Using Intravenous Perfluoropropane-Exposed Sonicated Dextrose Albumin", JACC, 26(1):33-40.
Harrison Robert H.
The Board of Regents of the University of Nebraska
LandOfFree
Thrombolytic agents and methods of treatment for thrombosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thrombolytic agents and methods of treatment for thrombosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thrombolytic agents and methods of treatment for thrombosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1452215